Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3192767 · 1 trial · 1 indication
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3192767 (Part A) | EXPERIMENTAL | Escalating doses of LY3192767 administered subcutaneously (SC). |
| Placebo (Part A) | PLACEBO_COMPARATOR | Placebo matching LY3192767 administered subcutaneously (SC). |
| LY3192767 (Part B) | EXPERIMENTAL | LY3192767 administered as a SC injection in one of three study periods. |
| Basal Insulin Peglispro (Part B) | ACTIVE_COMPARATOR | Basal insulin peglispro administered as a SC injection in one of three study periods. |
| Insulin Glargine (Part B) | ACTIVE_COMPARATOR | Insulin glargine administered as a SC injection in one of three study periods. |
| Name | Type | Description |
|---|---|---|
| LY3192767 | DRUG | Administered SC. |
| Basal Insulin Peglispro | DRUG | Administered SC. |
| Insulin Glargine | DRUG | Administered SC. |
| Placebo | DRUG | Administered SC. |
Inclusion Criteria: * Are overtly healthy males or females, as determined by medical history and physical examination * Have a body mass index (BMI) of \>18.5 and \<30.0 kilogram per square meter (kg/m²), inclusive Exclusion Criteria: * Are currently enrolled in a clinical trial involving an inve...
LY3192767 is an investigational small molecule being developed by Eli Lilly and Company. It is currently in Phase 1 clinical development. The drug has been studied in healthy participants, and its therapeutic area is classified as Other. As of now, it is not approved and remains in clinical testing.
LY3192767 is being studied for use in healthy participants, meaning it is not intended for a specific disease indication at this stage. The Phase 1 trial was designed to evaluate the drug in healthy volunteers, which is a common early step in clinical development to assess safety and tolerability.
LY3192767 is developed by Eli Lilly and Company, a pharmaceutical company traded on the stock exchange under the ticker symbol LLY. The company is conducting clinical trials to evaluate this investigational small molecule in healthy participants.
LY3192767 is in Phase 1 clinical development. The drug is investigational and has not been approved. A Phase 1 trial in healthy participants has been completed, and the drug is still in the early stages of clinical testing.
LY3192767 has one completed Phase 1 clinical trial, identified as NCT03025009, titled "A Study of LY3192767 in Healthy Participants." This trial enrolled 57 healthy volunteers in Germany, with participants aged 20 years and older. The study was randomized, double-blind, and placebo-controlled.
LY3192767 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The drug has been studied in a completed Phase 1 trial in healthy participants, but it has not received approval from regulatory authorities.